Lundbeck partners with Cradle to discover and optimize brain disorder treatments

H. Lundbeck A/S, a brain health biopharmaceutical company, has partnered with Cradle to leverage AI-powered protein design technology for discovering and optimizing biotherapeutics. The initial collaboration focuses on two antibody programs targeting CNS diseases, integrating experimental feedback loops to accelerate candidate development. This partnership strengthens Lundbeck’s broader AI strategy, complementing their recent collaboration with Denmark’s Gefion AI supercomputer to enhance discovery capabilities across their organization.